T2 Biosystems is a developer of a next-generation medical diagnostic platform that enables rapid and accurate diagnostic tests of all types on a single instrument. With two FDA-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. Its initial development efforts target sepsis, hemostasis, bacteria and Lyme disease, which are areas of significant unmet medical need. The Company is utilizing its proprietary T2 Magnetic Resonance platform to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier.